Caliway has completed submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical...
As cell and gene therapies move rapidly from pioneering clinical trials into commercial healthcare systems the industry is facing a defining inflection poi...
Neurotechnology company Neupulse has announced a first-of-its-kind wearable device proven to dramatically reduce the frequency and urge of tics in people l...
Biopharmaceutical leaders today are charting a course through unprecedented regulatory uncertainty and market turbulence. From shifting FDA and EMA approva...
Tjoapack, a leading global contract packaging organization, has announced a significant strategic investment to expand its operational footprint in the U.S...
-Pfizer Inc. (NYSE: PFE) today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and adolesc...
Approximately 25 non-ambulatory participants will receive sirolimus as part of the regimen in Cohort 8 of the ENDEAVOR study, which is expected to be...
The Muscular Dystrophy Association (MDA) called the U.S. Food and Drug Administration’s approval of Itvisma (onasemnogene abeparvovec-brve), ...
Partnership accelerates AGC Biologics' leadership in the AAV market, applying its BravoAAV™ platform to complex gene therapies for inherited blin...
Data reveals positive preliminary results for investigational agent tinostamustine as a potential first-in-class treatment for glioblastoma. -...
New state-of-the-art facility in Philadelphia provides integrated lab and collaboration space along with tailored guidance to help move advanced th...
In these diverse and dynamic markets, adaptation is not a strategy; it is a prerequisite for thriving. Success requires a fundamental shift in mind...
Initial commercial availability begins through an Early Experience Program with Penn Highlands Healthcare and Allegheny Health Network – Pr...
Halda to be acquired by Johnson & Johnson for $3.05 billion in cash Halda recently presented positive Phase 1/2 data for HLD-0915 in metastatic ca...
© 2026 Biopharma Boardroom. All Rights Reserved.
